Last reviewed · How we verify
Vandetanib, Selumetinib
Vandetanib, Selumetinib is a Small molecule drug developed by Cancer Research UK. It is currently in Phase 1 development.
At a glance
| Generic name | Vandetanib, Selumetinib |
|---|---|
| Sponsor | Cancer Research UK |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (PHASE2)
- SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients (PHASE2)
- A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vandetanib, Selumetinib CI brief — competitive landscape report
- Vandetanib, Selumetinib updates RSS · CI watch RSS
- Cancer Research UK portfolio CI
Frequently asked questions about Vandetanib, Selumetinib
What is Vandetanib, Selumetinib?
Vandetanib, Selumetinib is a Small molecule drug developed by Cancer Research UK.
Who makes Vandetanib, Selumetinib?
Vandetanib, Selumetinib is developed by Cancer Research UK (see full Cancer Research UK pipeline at /company/cancer-research-uk).
What development phase is Vandetanib, Selumetinib in?
Vandetanib, Selumetinib is in Phase 1.
Related
- Manufacturer: Cancer Research UK — full pipeline
- Compare: Vandetanib, Selumetinib vs similar drugs
- Pricing: Vandetanib, Selumetinib cost, discount & access